140 related articles for article (PubMed ID: 12707419)
1. Interferon beta-1a as an investigational treatment for CIDP.
Vallat JM; Hahn AF; Léger JM; Cros DP; Magy L; Tabaraud F; Bouche P; Preux PM
Neurology; 2003 Apr; 60(8 Suppl 3):S23-8. PubMed ID: 12707419
[TBL] [Abstract][Full Text] [Related]
2. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
4. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
5. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hadden RD; Sharrack B; Bensa S; Soudain SE; Hughes RA
Neurology; 1999 Jul; 53(1):57-61. PubMed ID: 10408537
[TBL] [Abstract][Full Text] [Related]
7. Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination.
Pirko I; Kuntz NL; Patterson M; Keegan BM; Weinshenker BG; Rodriguez M
Neurology; 2003 May; 60(10):1697-9. PubMed ID: 12771272
[TBL] [Abstract][Full Text] [Related]
8. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
9. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report.
Villa AM; Garcea O; Di Egidio M; Saizar R; Sica RE
Arq Neuropsiquiatr; 2004 Sep; 62(3B):892-4. PubMed ID: 15476092
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
Hahn AF; Bolton CF; Zochodne D; Feasby TE
Brain; 1996 Aug; 119 ( Pt 4)():1067-77. PubMed ID: 8813271
[TBL] [Abstract][Full Text] [Related]
14. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.
Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu MG; Martinelli V; Milanese C; Moiola L; Milani N; La Mantia L; Patti F; Pozzilli C; Trojano M; Comi G; Zaffaroni M;
Neurol Sci; 2007 Jun; 28(3):127-32. PubMed ID: 17603763
[TBL] [Abstract][Full Text] [Related]
15. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
Lampl C; You X; Limmroth V
Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
17. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
[TBL] [Abstract][Full Text] [Related]
18. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
19. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis.
Matsuse D; Ochi H; Tashiro K; Nomura T; Murai H; Taniwaki T; Kira J
Intern Med; 2005 Jan; 44(1):68-72. PubMed ID: 15704667
[TBL] [Abstract][Full Text] [Related]
20. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
